Page 67 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy
P. 67
Immunotherapy Checkpoint Inhibition
Immuno checkpoint inhibition
only 16 patients had gastric cancer with overall response rate outcome of 25%[21] (Table 1). Other studies are ongoing (table 2). Thus confidence in results will be boosted. Intriguingly, anti-CTLA4 strategies appear much less effective as compared to anti-PD1/PD-L1 strategies and it would be interesting to explore whether is a reflection of the fundamental biological immunology of advanced gastric cancer. Despite a lack of fundamental understanding as to the specific sensitivity of the gastric cancer to PD1-PD-L1 checkpoint inhibition, it is fair to say that It molecules targeting the latter system appear a promising novel avenue for the treatment of advanced gastric cancer. We shall discuss the various trials below.
61
65
3
